Ophthalmology

Audrey Abella, 2 days ago

The pupil of the eye may independently predict all‐cause mortality and readmission due to heart failure (HF), suggesting its prognostic predictive capability in patients with HF, a retrospective analysis has shown.

AI-enabled dashboard monitors visual loss in glaucoma

Stephen Padilla, 16 Sep 2020

An artificial intelligence (AI) dashboard for examining glaucomatous functional loss, developed using a large visual field (VF) dataset containing a broad spectrum of visual deficit types, provides clinicians with a user-friendly tool to determine the severity of glaucomatous vision deficit and the spatial extent of the damage, as well as monitor disease progression, reports a study.

Foods rich in multiple nutrients promote eye health

15 Sep 2020

Increased dietary intake of multiple nutrients, such as minerals, vitamins, and carotenoids, protects against the risk of progression to late age-related macular degeneration, specifically geographic atrophy, according to a study.

Myopic macular degeneration in Asians: Who’s at risk?

12 Sep 2020

The risk of developing myopic macular degeneration (MMD) is high among older individuals, women, those with lower education, greater myopia severity, and longer axial length, according to data from a consortium of Asian studies. Furthermore, myopic spherical equivalent is the strongest single predictor of MMD.

Novel drug delivery system reduces treatment burden in neovascular AMD

Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 04 Sep 2020

Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.